Medical Plus s.r.o.

The department at Medical Plus s.r.o. is dedicated to improving care for patients with joint and bone disorders, testing new therapies aimed at reducing pain and slowing disease progression. Recent work emphasizes rheumatoid arthritis and psoriatic arthritis as well as conditions that affect the spine and weight‑bearing joints such as axial spondyloarthritis, knee osteoarthritis and osteoporosis.

• Rheumatoid arthritis
• Psoriatic arthritis
• Knee osteoarthritis
• Axial spondyloarthritis
• Osteoporosis

With 37 active trials and 11 investigators, the site is advancing both disease‑modifying agents and symptomatic treatments for musculoskeletal health.

Clinical research at the facility explores autoimmune conditions, seeking safer and more effective ways to control systemic inflammation. Studies target systemic lupus erythematosus, Sjögren’s syndrome, giant cell arteritis and polymyalgia rheumatica, evaluating novel biologics and targeted small molecules.

• Systemic lupus erythematosus
• Sjögren’s syndrome
• Giant cell arteritis
• Polymyalgia rheumatica
• Autoimmune arthritis

The program aims to improve long‑term safety and disease‑activity outcomes for patients with immune‑mediated disorders.

Researchers are investigating therapies that address excess body weight and related metabolic complications. Ongoing trials assess the impact of investigational agents on obesity, overweight, and type 2 diabetes, as well as on severe lipid abnormalities such as hypertriglyceridemia.

• Obesity
• Overweight
• Type 2 diabetes
• Severe hypertriglyceridemia
• Metabolic syndrome

The goal is to demonstrate weight reduction and improved metabolic markers while maintaining safety.

The site’s portfolio includes investigations of conditions where skin and connective tissue are affected by systemic inflammation. Trials focus on psoriatic arthritis and its skin counterpart, evaluating agents that may simultaneously improve joint function and skin lesions.

• Psoriatic arthritis
• Psioriasis
• Connective‑tissue involvement in rheumatic disease

By linking dermatologic outcomes with rheumatologic response, the research seeks integrated therapeutic benefits.

Although primarily a rheumatology center, the department also monitors ocular manifestations of systemic disease, aiming to protect vision while treating the underlying condition. Studies include patients with uveitis associated with inflammatory arthritis and evaluate systemic therapies for ocular benefit.

• Uveitis linked to rheumatic disease
• Dry eye in autoimmune disorders
• Retinal involvement in systemic inflammation

The approach integrates eye health into broader disease‑management strategies.

Research at the clinic extends to oral and maxillofacial aspects of rheumatic illnesses, investigating how systemic inflammation influences the mouth and jaw. Efforts include evaluating treatments for temporomandibular joint involvement and oral dryness in autoimmune patients.

• Temporomandibular joint disorders
• Oral dryness (xerostomia)
• Dental health in systemic disease

These studies aim to improve quality of life by addressing both dental and rheumatologic symptoms.